Evidence map›Paper›PMID 41755881›Full record

ArticleAddictive behaviors reports2026

Treatment preferences of patients receiving opioid agonist therapy in spain: a discrete choice experiment.

M L Dorado García, Z Alonso Ganuza, A I Henche Ruíz, A Marcos Flores, T Orengo Caus, R F Palma Álvarez, M A Rodríguez Cejas, A Sánchez Máñez, P Vega Astudillo, D Sucunza Guibert and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addictive behaviors reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M L Dorado GarcíaHospital General Universitario de Valencia, Addictive Disorder Unit Guillem de Castro, Valencia, Spain.
Z Alonso GanuzaUribe Kosta Mental Health Center, Biscay, Basque Country, Spain.
A I Henche RuízAddictive Behaviors Unit, SESCAM, Toledo, Castile-La Mancha, Spain.
A Marcos FloresDrug Addiction Care Center (Red Cross), Valladolid, Castile and Leon, Spain.
T Orengo CausAddictive Disorders Unit Grao, Valencia, Spain.
R F Palma ÁlvarezDepartment of Mental Health, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
M A Rodríguez CejasCoria del Río Addiction Treatment Center, Seville, Spain.
A Sánchez MáñezAddictive Disorders Unit, Paterna, Valencia, Spain.
P Vega AstudilloTetuán Drug Addiction Care Center, Madrid Salud, Madrid City Council, Madrid, Spain.
D Sucunza GuibertCamurus SL, Madrid, Spain.
M Gómez-BarreraPharmacoeconomics and Outcomes Research Iberia (PORIB) SL, Madrid, Spain.
M Yébenes CortésPharmacoeconomics and Outcomes Research Iberia (PORIB) SL, Madrid, Spain.
A Crespo PorteroMurcia Addictive Disorders Unit, Murcia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To explore the preferences of patients with opioid use disorder (OUD) regarding opioid agonist treatment (OAT). Methods: The present study was a descriptive, observational, cross-sectional study in OUD patients on treatment for at least 3 months, using one of the pharmacological options available in Spain: methadone (MTD) tablets, MTD oral solution, sublingual buprenorphine/naloxone (SL BPN/NX) or long-acting injectable buprenorphine (LAIB). A discrete choice experiment (DCE) assessed which medication attributes patients prioritized when selecting a hypothetical ideal treatment for their disease. Results: 128 patients from 10 different addiction centres (AC) participated in this study. Treatment groups were balanced: liquid MTD: 28.1%; LAIB: 25%; SL BPN/NX: 24.2%, and MTD tablets: 22.7%. The mean age of the patients was 51 years, and 80% were men. For the total sample, the frequency of administration (Relative importance [RI]: 42.07%) (monthly/weekly vs. daily), route of administration (RI: 22.12%) (oral/SL vs. injectable), and cost (RI = 19.38%) (no co-payment vs. co-payment) were the most impactful factors. For LAIB patients, frequency of administration was the most preferred attribute ahead of cost (second) and performance of daily activities (third). Administration route in these patients ranked fourth. Preferences for these criteria were equal between MTD and SL BPN/NX. Conclusion: Frequency of administration was the main attribute across all treatment groups. Among patients treated with MTD or SL BPN/NX, route of administration and cost were the second and third most relevant attributes, whereas in LAIB patients, cost and the impact on daily activities ranked second and third, respectively.

Indexed as

Discrete choice experimentLong-acting injectable buprenorphineOpioid Dependence TreatmentOpioid use disorderPatient preference

Identifiers

PMID41755881
PMCPMC12933860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.